By Daniella Parra
Vaxxinity, Inc. (Nasdaq: VAXX) said it appointed Peter Powchik, M.D. as Executive Vice President, Global Scientific Director overseeing its scientific direction and lead development efforts.
Powchik was previously Senior Vice President at Regeneron Pharmaceuticals, the company said. Additionally, Ulo Palm, M.D., will transition from Chief Medical Officer to senior advisor, it said.
“It’s a pivotal time at Vaxxinity,” said Powchik. “Our laboratories have come online and are generating the data that we hope will help launch a revolution in proactive immunization. Clinical data have demonstrated that our technology breaks immune tolerance to targets of interest, and is well tolerated and easy to administer.”